C4 Therapeutics, Inc.

C4 Therapeutics will present preliminary data from the ongoing Phase 1/2 study of CFT1946, our novel BiDAC™ degrader in mutant BRAF V600 solid tumors, at the ESMO - European Society for Medical Oncology Congress being held September 13-17 in Barcelona. Learn more: https://bit.ly/3WnpgUq #ESMO24

C4 Therapeutics will participate in a fireside chat at the UBS Targeted Protein Degradation Day occurring virtually on July 15. Learn more: https://bit.ly/4eRJpZU

As we advance degraders through clinical trials, it is crucial to have a seasoned regulatory strategy leader who understands the landscape of oncology drug development, approval and path to commercialization. At C4T that leader is Mary Christian, senior vice president, regulatory. Mary has over 20 years of industry experience, including regulatory approvals, managing strategic collaborations in oncology and overseeing the expansion of commercial asset indications. Learn more about Mary and our leadership team: https://bit.ly/3EQBafX

Cemsidomide, an orally bioavailable degrader, is currently being evaluated in a Phase 1/2 clinical trial as a potential treatment for multiple myeloma and non-Hodgkin's lymphoma. Learn more on our website: https://bit.ly/4bsj5TU #TPD

On Juneteenth, we recognize the continued urgency for true equality around the world and the importance of supporting black communities. To support black owned businesses in Boston, check out the Seaport X Black Owned Bos. market series: https://bit.ly/4501T66

In honor of #Pride and our commitment to bringing our unique selves to C4T, Nicole Follmer, a member of our DEI Council, led a discussion with Ashley Boyd, Leonard Reyno and Catherine Solovay, PMP about allyship. #PrideMonth

It’s that time of year! We’re excited to enter summer the C4T way - welcoming our 2024 intern class brought to us in partnership with Project Onramp. Our whole team looks forward to working with this motivated group of students eager to learn about career opportunities in life sciences. Our interns will work across multiple functions at C4T, contributing to the cell pharmacology, program management, regulatory and translational medicine teams. Welcome, Cristina Vasquez Genesis Castillo Kaitlyn Taliaferro Fua Nasu!

We’re excited to announce the appointment of Ron Cooper as chairman of our Board of Directors as C4T continues its evolution to become a fully integrated biotech. Ron brings decades of global pharmaceutical and biotech leadership across drug development, advancing treatments through discovery, development and commercialization. The C4T team is thrilled to have Ron’s experience as we advance our targeted protein degradation science for patients. Read more in our latest release: https://bit.ly/45lRJwO

Have you heard about Deggie? Our integrated laboratory automation machine is a tool that enables our #TPD science, allowing us to efficiently manage the wide array of biochemical and cellular assays needed to screen and characterize potential drug molecules. To us, Deggie symbolizes our science and the work we’ve done to create new, transformative medicines. Read Deggie’s story here: https://bit.ly/4apfeFR

Happy #Pride! At C4T we’re committed to making sure everyone can bring their unique self to work. This month, we’re celebrating Pride and LGBTQIA+ communities, both at C4T and in our own city. In partnership with Watertown Community Foundation, we volunteered to paint hearts carrying messages of inclusivity and hung them around Watertown to help spread the joy of Pride. Within C4T, we’ve hung notes that answer the question, “How do you help others bring their unique self to work?” to encourage all of us to create a culture of belonging. We’re also looking forward to our DEI Council leading a discussion on allyship! #PrideMonth